Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.50
Bid: 80.00
Ask: 85.00
Change: 0.00 (0.00%)
Spread: 5.00 (6.25%)
Open: 82.50
High: 82.50
Low: 82.50
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options and PDMR dealing

23 Feb 2022 07:00

RNS Number : 4852C
Feedback PLC
23 February 2022
 

 

Feedback plc

 

Grant of Options and PDMR dealing

 

London, 23 February 2022: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that it has granted a total of 162,692,640 options to subscribe for new ordinary shares in the Company under the Company's Non-tax-advantaged and EMI Share Option Schemes (together, the "Options") to a certain number of its directors and employees, as detailed below.

 

The Options are being issued to support staff retention and to further align overall reward with increasing shareholder value.

 

All Options are exercisable at a price of 0.7 pence per share, reflecting the price at which the Company last completed an equity fundraise in November 2021 and representing a premium of 3 per cent to the closing share price on the last trading day before this announcement.

 

145,237,200 Options granted to the Executive Directors and other persons discharging managerial responsibilities ("PDMRs") below (being 89 percent. of Options granted) will vest in three equal tranches over the next three financial years, conditional on achieving certain share price targets (based on a 60 calendar day volume weighted average share price) as follows:

 

· One-third will vest if the share price reaches at least 1.20p, during the period commencing 31/05/2022 and ending 31/05/2025;

 

· One-third will vest if the share price reaches at least 1.86p during the period commencing 31/05/2023 and ending 31/05/2025; and

 

· One-third will vest if the share price reaches at least 3.0p during the period commencing 31/05/2024 and ending 31/05/2025.

 

Options being granted to the Executive Directors and PDMRs which are subject to the share price performance conditions above:

 

 

Non tax-Advantaged Options

 

EMI Options

Total options held (including existing options)

 

 

 

 

Tom Oakley, CEO

83,846,520

-

106,677,349

Anesh Patel, CFO

17,624,520

35,714,160

53,338,680

Michael Hayball, CTO

-

2,013,000

9,213,000

Stephen Brown, Chief Regulatory & Compliance Officer

-

2,013,000

9,213,000

Stephen McAteer, COO

-

2,013,000

4,013,000

Nicolas Mayhew, Chief Sales & Marketing Officer

-

2,013,000

4,013,000

 

7,855,440 EMI Options (with time-based vesting conditions only) were awarded to 10 employees, with one-third vesting on each of the first, second and third anniversaries of grant.

 

In addition, Rory Shaw, Non-Executive Chairman, has been granted 9,600,000 Non tax-Advantaged Options (taking the total number of share options held by him to 17,400,000), primarily for retention purposes. Alongside the Executive management team, Rory has key relationships with NHS bodies and Community Diagnostic Centres (CDC), potential customers for the Company's product suite. These Options have time-based vesting conditions only and are not linked to share price performance conditions, with one-third vesting on each of the first, second and third anniversaries of grant.

 

The Options are exercisable for a period of 5 years from the vesting date.

 

The Options represent in aggregate 6.1% of the Company's existing issued share capital.

 

Following the grant of the Options and taking into account existing options, the Company has a total of 217,516,909 options to subscribe for ordinary shares in the Company in issue, representing 8.2% of the Company's issued share capital at the date of this announcement.

 

The FCA notifications, made in accordance with the requirements of the EU Market Abuse Regulation, are appended below.

 

Further information on Feedback and its products can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Anesh Patel, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

 

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

About Feedback

 

Feedback plc is a specialist clinical communications business, with a mission to improve the efficiency and quality of communications for frontline clinicians and hospitals with a key focus on building solutions that enhance access to high quality patient data.

 

Feedback has developed a toolkit of clinical communications apps. Its core, regulatory approved product is Bleepa, a revolutionary medical imaging app enabling remote and secure communications between frontline clinicians and teams. CareLocker is an evolutionary GDPR compliant patient-centric cloud architecture - its proprietary technology enables an easy route to creation and mobilisation of individual healthcare records. Bleepa Box is a specialist tool to enable image transfer from remote settings to the Bleepa platform over mobile networks.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Rory Shaw

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Non-Executive Chairman

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Non-tax-advantaged Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

9,600,000 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Tom Oakley

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Non-tax-advantaged Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

83,846,520 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Anesh Patel

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Chief Financial Officer

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Non-tax-advantaged Options and EMI Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

53,338,680 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 Michael Hayball

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Director of Feedback Medical Limited

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

EMI Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

2,013,000 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 Stephen McAteer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Director of Feedback Medical Limited

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

EMI Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

2,013,000 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 Nicolas Mayhew

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Director of Feedback Medical Limited

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

EMI Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

2,013,000 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 Stephen Brown

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR - Director of Feedback Medical Limited

b)

 

Initial notification /Amendment

 

 

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Feedback plc

b)

 

LEI

 

 

213800UGOF2GT2U2RV90

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

EMI Options to subscribe for Ordinary Shares of 0.25p each

 

 

 

Identification code (ISIN) for Feedback plc ordinary shares:

GB0003340550

b)

 

Nature of the transaction

 

Issue of options to subscribe for Ordinary Shares in consideration of

payment of fees

c)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

Exercise price of 0.7p

2,013,000 shares

 

 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

 

Date of the transaction

 

23 February 2022

 

f)

 

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHVLLFLLLLFBBV
Date   Source Headline
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.